Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris
Public ClinicalTrials.gov record NCT02651220. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of adapalene and benzoyl peroxide gel, 0.3%/2.5% (Actavis Laboratories UT, Inc.) to Epiduo® Forte (adapalene and benzoyl peroxide) gel 0.3%/2.5% (Galderma) in the treatment of Acne Vulgaris
Study identification
- NCT ID
- NCT02651220
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,001 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 40 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2015 (Type not available)
- Primary completion
- Apr 2016 (Actual)
- Completion
- Oct 2016 (Actual)
- Last update posted
- Jun 23, 2020
2015 – 2016
United States locations
- U.S. sites
- 18
- U.S. states
- 8
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 103 | Mesa | Arizona | 85202 | — |
| Site 109 | Tucson | Arizona | 85712 | — |
| Site 112 | Anaheim | California | 92804 | — |
| Site 110 | Long Beach | California | 90813 | — |
| Site 111 | Los Angeles | California | 92210 | — |
| Site 104 | San Diego | California | 92108 | — |
| Site 113 | West Covina | California | 91790 | — |
| Site 101 | Brandon | Florida | 33511 | — |
| Site 119 | Jacksonville | Florida | 32256 | — |
| Site 114 | Miami | Florida | 33015 | — |
| Site 115 | Miami | Florida | 33175 | — |
| Site 116 | Miramar | Florida | 33027 | — |
| Site 102 | Arlington Heights | Illinois | 60005 | — |
| Site 105 | Carmel | Indiana | 46032 | — |
| Site 120 | New Albany | Indiana | 47150 | — |
| Site 107 | Henderson | Nevada | 89052 | — |
| Site 106 | High Point | North Carolina | 27262 | — |
| Site 108 | Rhinelander | Wisconsin | 54501 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02651220, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 23, 2020 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02651220 live on ClinicalTrials.gov.